Keros Therapeutics (KROS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $10.66, -3.96% vs the prior close of $11.10.
- Volume 169.64K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
KROS slides 4.0% to $10.66, a 1-month low. Closed at $10.66, -3.96% vs the prior close of $11.10. Day range $10.65–$11.13, opened at $11.11.
KROS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — KROS slides 4.0% to $10.66, a 1-month low
- Closed at $10.66, -3.96% vs the prior close of $11.10. Day range $10.65–$11.13, opened at $11.11.
- Volume was 169.64K shares, 0.9x its 50-day average of 191.95K.
- Price is -4.5% vs its 50-day average ($11.16) and -14.3% vs its 200-day average ($12.44).
- 52-week range $9.69–$22.55; today's close sits at 8% of that range, 52.7% below the 52-week high.
Oct 15, 2026 — KROS rises 0.5% to $11.10
- Closed at $11.10, +0.45% vs the prior close of $11.05. Day range $10.98–$11.40, opened at $11.13.
- Volume was 96.70K shares, 0.5x its 50-day average of 196.72K — lighter than usual.
- Price is -0.6% vs its 50-day average ($11.16) and -11.1% vs its 200-day average ($12.49).
- 52-week range $9.69–$22.55; today's close sits at 11% of that range, 50.8% below the 52-week high.
Oct 14, 2026 — KROS dips 1.6% to $11.05, 3 down days in a row
- Closed at $11.05, -1.60% vs the prior close of $11.23. Day range $10.92–$11.30, opened at $11.07.
- Volume was 159.10K shares, 0.8x its 50-day average of 199.08K.
- Price is -0.8% vs its 50-day average ($11.14) and -11.9% vs its 200-day average ($12.54).
- 52-week range $9.69–$22.55; today's close sits at 11% of that range, 51.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — KROS slides 3.3% to $11.23
- Closed at $11.23, -3.27% vs the prior close of $11.61. Day range $11.19–$11.69, opened at $11.65.
- Volume was 144.30K shares, 0.7x its 50-day average of 199.27K.
- Price is +0.9% vs its 50-day average ($11.12) and -10.8% vs its 200-day average ($12.59).
- 52-week range $9.69–$22.55; today's close sits at 12% of that range, 50.2% below the 52-week high.
Oct 12, 2026 — KROS dips 2.8% to $11.61
- Closed at $11.61, -2.85% vs the prior close of $11.95. Day range $11.58–$12.08, opened at $11.77.
- Volume was 223.70K shares, 1.1x its 50-day average of 197.70K.
- Price is +4.6% vs its 50-day average ($11.10) and -8.1% vs its 200-day average ($12.64).
- 52-week range $9.69–$22.55; today's close sits at 15% of that range, 48.5% below the 52-week high.
Oct 9, 2026 — KROS rises 2.7% to $11.95, a 3-month high, 3 up days in a row
- Closed at $11.95, +2.66% vs the prior close of $11.64. Day range $11.49–$12.26, opened at $11.58.
- Volume was 194.40K shares, 1.0x its 50-day average of 196.54K.
- Price is +7.9% vs its 50-day average ($11.07) and -5.8% vs its 200-day average ($12.69).
- 52-week range $9.69–$22.55; today's close sits at 18% of that range, 47.0% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — KROS jumps 3.8% to $11.64
- Closed at $11.64, +3.84% vs the prior close of $11.21. Day range $10.99–$11.76, opened at $11.13.
- Volume was 245.70K shares, 1.3x its 50-day average of 194.91K.
- Price is +5.5% vs its 50-day average ($11.04) and -8.6% vs its 200-day average ($12.73).
- 52-week range $9.69–$22.55; today's close sits at 15% of that range, 48.4% below the 52-week high.
Oct 7, 2026 — KROS rises 1.8% to $11.21
- Closed at $11.21, +1.82% vs the prior close of $11.01. Day range $10.81–$11.34, opened at $10.81.
- Volume was 196.00K shares, 1.0x its 50-day average of 194.26K.
- Price is +1.9% vs its 50-day average ($11.00) and -12.3% vs its 200-day average ($12.78).
- 52-week range $9.69–$22.55; today's close sits at 12% of that range, 50.3% below the 52-week high.
Oct 6, 2026 — KROS slides 4.4% to $11.01
- Closed at $11.01, -4.43% vs the prior close of $11.52. Day range $10.95–$11.63, opened at $11.56.
- Volume was 185.30K shares, 1.0x its 50-day average of 193.70K.
- Price is +0.3% vs its 50-day average ($10.98) and -14.1% vs its 200-day average ($12.82).
- 52-week range $9.69–$22.55; today's close sits at 10% of that range, 51.2% below the 52-week high.
Oct 5, 2026 — KROS rises 1.4% to $11.52
- Closed at $11.52, +1.41% vs the prior close of $11.36. Day range $11.07–$11.56, opened at $11.38.
- Volume was 132.40K shares, 0.7x its 50-day average of 193.86K.
- Price is +5.1% vs its 50-day average ($10.96) and -10.5% vs its 200-day average ($12.87).
- 52-week range $9.69–$22.55; today's close sits at 14% of that range, 48.9% below the 52-week high.
Oct 2, 2026 — KROS rises 0.9% to $11.36
- Closed at $11.36, +0.89% vs the prior close of $11.26. Day range $11.01–$11.44, opened at $11.38.
- Volume was 231.50K shares, 1.2x its 50-day average of 193.58K.
- Price is +3.9% vs its 50-day average ($10.94) and -12.1% vs its 200-day average ($12.92).
- 52-week range $9.69–$22.55; today's close sits at 13% of that range, 49.6% below the 52-week high.
KROS latest news & SEC filings
Every SEC filing by or about KROS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 16, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 11, 2026 · Form DEL AM — DEL AM filing
DEL AM filing
Sep 10, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 8, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tanini Annita sold 1,224 shares at $10.29 (≈$12.59K) on Aug 18, 2026
- Tanini Annita sold 1,224 shares at $10.29 (≈$12.59K) on Aug 18, 2026
- Tanini Annita sold 1,224 shares at $10.29 (≈$12.59K) on Aug 18, 2026
- Tanini Annita sold 1,224 shares at $10.29 (≈$12.59K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Lerner Lorena Raquel sold 3,568 shares at $10.29 (≈$36.71K) on Aug 18, 2026
- Lerner Lorena Raquel sold 3,568 shares at $10.29 (≈$36.71K) on Aug 18, 2026
- Lerner Lorena Raquel sold 3,568 shares at $10.29 (≈$36.71K) on Aug 18, 2026
- Lerner Lorena Raquel sold 3,568 shares at $10.29 (≈$36.71K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Cho Esther sold 4,485 shares at $10.29 (≈$46.15K) on Aug 18, 2026
- Cho Esther sold 4,485 shares at $10.29 (≈$46.15K) on Aug 18, 2026
- Cho Esther sold 4,485 shares at $10.29 (≈$46.15K) on Aug 18, 2026
- Cho Esther sold 4,485 shares at $10.29 (≈$46.15K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 20, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Newton Charles W. sold 551 shares at $10.30 (≈$5.68K) on Aug 18, 2026
- Newton Charles W. sold 551 shares at $10.30 (≈$5.68K) on Aug 18, 2026
- Newton Charles W. sold 551 shares at $10.30 (≈$5.68K) on Aug 18, 2026
- Newton Charles W. sold 551 shares at $10.30 (≈$5.68K) on Aug 18, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bienaime Jean Jacques bought 1,000 shares at $10.27 (≈$10.27K) on Aug 17, 2026
- Bienaime Jean Jacques bought 1,000 shares at $10.27 (≈$10.27K) on Aug 17, 2026
- Bienaime Jean Jacques bought 1,000 shares at $10.27 (≈$10.27K) on Aug 17, 2026
- Bienaime Jean Jacques bought 1,000 shares at $10.27 (≈$10.27K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 3, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $18.17M) (-100.0% vs Jun 30, 2025)
- Net income: -$28.71M (prior year -$30.70M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.45 (prior year -$0.76) (loss widened vs Jun 30, 2025)
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade KROS
- Last results release: Aug 3, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 4, 2026, Nov 5, 2025. Based on that rhythm, the next report is likely around Nov 2, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.05% (largest 4.4%).
- Liquidity: about 177.28K shares (≈$1.89M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $10.66 vs a range of $9.69–$22.55 (8% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 9 open-market buys, 16 sales; latest: Lorena Raquel Lerner sold 3,568 shares on Aug 18, 2026.
- Latest filings: 8-K Sep 29, 2026; 8-K Sep 28, 2026; 8-K Sep 8, 2026.
- Share count: 19.83M shares outstanding (Jul 27, 2026), -51.2% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
KROS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11.11 | 11.13 | 10.65 | 10.66 | 169.64K |
| Oct 15, 2026 | 11.13 | 11.40 | 10.98 | 11.10 | 96.70K |
| Oct 14, 2026 | 11.07 | 11.30 | 10.92 | 11.05 | 159.10K |
| Oct 13, 2026 | 11.65 | 11.69 | 11.19 | 11.23 | 144.30K |
| Oct 12, 2026 | 11.77 | 12.08 | 11.58 | 11.61 | 223.70K |
| Oct 9, 2026 | 11.58 | 12.26 | 11.49 | 11.95 | 194.40K |
| Oct 8, 2026 | 11.13 | 11.76 | 10.99 | 11.64 | 245.70K |
| Oct 7, 2026 | 10.81 | 11.34 | 10.81 | 11.21 | 196.00K |
| Oct 6, 2026 | 11.56 | 11.63 | 10.95 | 11.01 | 185.30K |
| Oct 5, 2026 | 11.38 | 11.56 | 11.07 | 11.52 | 132.40K |
| Oct 2, 2026 | 11.38 | 11.44 | 11.01 | 11.36 | 231.50K |
| Oct 1, 2026 | 11.38 | 11.44 | 11.08 | 11.26 | 140.20K |
| Sep 30, 2026 | 11.25 | 11.58 | 11.16 | 11.40 | 131.20K |
| Sep 29, 2026 | 11.24 | 11.46 | 11.15 | 11.19 | 118.30K |
| Sep 28, 2026 | 11.33 | 11.41 | 10.93 | 11.28 | 208.60K |
| Sep 25, 2026 | 11.54 | 11.70 | 11.28 | 11.62 | 216.10K |
| Sep 24, 2026 | 11.60 | 11.60 | 10.97 | 11.55 | 284.40K |
| Sep 23, 2026 | 11.68 | 11.82 | 11.47 | 11.63 | 157.50K |
| Sep 22, 2026 | 11.54 | 12.05 | 11.43 | 11.73 | 189.80K |
| Sep 21, 2026 | 11.31 | 11.60 | 11.08 | 11.48 | 120.70K |
About Keros Therapeutics
Keros Therapeutics (KROS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in LEXINGTON, MA. Fiscal year ends December 31. SEC CIK 1664710.
KROS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jean Jacques Bienaime | Director | Aug 19, 2026 |
| Nima Farzan | Director | Jun 8, 2026 |
| Carl L Gordon | Director | Dec 18, 2025 |
| Mary Ann Gray | Director | Jun 5, 2026 |
| Tomer Kariv | Director | Oct 17, 2025 |
| Julius Knowles | Director | Jun 8, 2026 |
| Charles W. Newton | Director | Aug 20, 2026 |
| Ran Nussbaum | Director | Oct 17, 2025 |
| Advisors Llc Orbimed | Director | Dec 18, 2025 |
| Capital Gp Vii Llc Orbimed | Director | Dec 18, 2025 |
| Genesis Gp Llc Orbimed | Director | Dec 18, 2025 |
| Anne Prener | Director | Jul 6, 2026 |
| Jasbir Seehra | CHIEF EXECUTIVE OFFICER | Apr 6, 2026 |
| Alpna Seth | Director | Jun 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Esther Cho | Chief Legal Officer | Aug 20, 2026 |
| Lorena Raquel Lerner | Chief Scientific Officer | Aug 20, 2026 |
| Keith Regnante | CHIEF FINANCIAL OFFICER | Feb 26, 2026 |
| Jasbir Seehra | CHIEF EXECUTIVE OFFICER | Apr 6, 2026 |
| Annita Tanini | Corp. Controller & VP, Finance | Aug 20, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Lorena Raquel Lerner | Sale | 3,568 | $10.29 |
| Aug 18, 2026 | Lorena Raquel Lerner | Sale | 3,568 | $10.29 |
| Aug 18, 2026 | Lorena Raquel Lerner | Sale | 3,568 | $10.29 |
| Aug 18, 2026 | Lorena Raquel Lerner | Sale | 3,568 | $10.29 |
| Aug 18, 2026 | Esther Cho | Sale | 4,485 | $10.29 |
| Aug 18, 2026 | Esther Cho | Sale | 4,485 | $10.29 |
| Aug 18, 2026 | Esther Cho | Sale | 4,485 | $10.29 |
| Aug 18, 2026 | Esther Cho | Sale | 4,485 | $10.29 |
| Aug 18, 2026 | Annita Tanini | Sale | 1,224 | $10.29 |
| Aug 18, 2026 | Annita Tanini | Sale | 1,224 | $10.29 |
| Aug 18, 2026 | Annita Tanini | Sale | 1,224 | $10.29 |
| Aug 18, 2026 | Annita Tanini | Sale | 1,224 | $10.29 |
| Aug 18, 2026 | Charles W. Newton | Sale | 551 | $10.30 |
| Aug 18, 2026 | Charles W. Newton | Sale | 551 | $10.30 |
| Aug 18, 2026 | Charles W. Newton | Sale | 551 | $10.30 |
KROS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $244.06M | $87.01M | 2.30 | $107.50M |
| Dec 31, 2024 | $3.55M | $-187.35M | -5.00 | $-160.87M |
| Dec 31, 2023 | $151.00K | $-152.99M | -5.20 | $-124.51M |
| Dec 31, 2022 | $0 | $-104.68M | -4.15 | $-70.06M |
| Dec 31, 2021 | $20.10M | $-58.74M | -2.52 | $-62.15M |
Latest balance sheet: total assets $287.60M, total liabilities $25.28M, cash $257.61M (as of Jun 30, 2026).
KROS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 3, 2026 | 8-K Item 2.02 (results) | $10.11 |
| May 14, 2026 | 8-K Item 2.02 (results) | $10.99 |
| Mar 4, 2026 | 8-K Item 2.02 (results) | $13.77 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $15.65 |
| Oct 15, 2025 | 8-K Item 2.02 (results) | $14.49 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $14.41 |
| May 6, 2025 | 8-K Item 2.02 (results) | $13.76 |
| Feb 26, 2025 | 8-K Item 2.02 (results) | $10.94 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $66.45 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on KROS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.